2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

5825 Comparative analysis of disease burden and proliferative index as a predictor of primary resistance to anti-BCMA- and anti-GPRC5D-directed T-cell engagers in relapsed/refractory multiple myeloma

Will Bo Li, Jiahuai Kang2, Shaji Kumar, MD3, Prashant Kapoor, MD4, Angela Dispenzieri, MD5, Francis Buadi, MD6, David Dingli, MD, PhD7, Saurabh Zanwar, MBBS, MD8, Dragan Jevremovic, MD PhD9, Suzanne Hayman, MD10, Nelson Leung, MD11, Joselle M Cook, M.D.12, Nadine Abdallah I, MD13, Moritz Binder, MD, MPH14, Eli Muchtar, MD15, Rahma Warsame, MD16, Taxiarchis Kourelis, MD17, Ronald Go, MD18, Yi Hwa, DNP19, Miriam Hobbs, CNP20, Amie Fonder, PA-C21, Yi Lin Jr, MD, PhD22, Morie Gertz23, S. Vincent Rajkumar, MD24, Wilson Gonsalves, MD25
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States

Background  

Bispecific T-cell engagers (TCEs) targeting BCMA and GPRC5D have transformed the treatment of relapsed/refractory multiple myeloma (RRMM). However, primary resistance to anti-BCMA TCEs is more common in patients with high bone marrow (BM) disease burden, potentially due to soluble BCMA-mediated TCE sequestration, thereby limiting target engagement. Whether bone marrow plasma cell (BMPC) proliferative index independently influences response to anti-BCMA TCEs, and whether either BMPC burden or proliferative index similarly impacts responses to anti-GPRC5D TCEs, remains unknown. We therefore evaluated the association of baseline BMPC burden and proliferative index with primary resistance to either teclistamab or talquetamab monotherapy in patients with RRMM. 

Methods 

Patients with RRMM treated with teclistamab or talquetamab monotherapy at our institution between January 2023 and June 2026 were retrospectively identified. Only patients who completed at least the first treatment cycle, including step-up dosing, and had a pre-treatment BM evaluation were included. BMPC% was recorded, and the BMPC proliferative index was assessed using the Plasma Cell Proliferation (PCPRO) assay, a flow cytometric test that quantifies the percentage of clonal plasma cells in S-phase of the cell cycle. Electronic health records were reviewed for patient demographics, disease characteristics, prior therapies, and clinical outcomes. Primary resistance was defined as failure to achieve at least a partial response according to the IMWG response criteria. Statistical analyses were performed using JMP version 18.0.1 (SAS Institute Inc). 

Results 

We identified two cohorts of patients with RRMM treated with either teclistamab (n = 47) or talquetamab (n = 47) monotherapy. The median age at the start of treatment was 71 years for teclistamab and 66 years for talquetamab, with a median of 4 prior lines of therapy in both cohorts (range, 1–11 and 2–11, respectively). High-risk cytogenetic abnormalities were present in 85% (40/47) of teclistamab and 98% (45/46) of talquetamab-treated patients. Prior to TCE initiation, the median BMPC percentage was 30% (range, 0–95%) in the teclistamab cohort and 20% (range, 0–95%) in the talquetamab cohort, with 40% (19/47) and 36% (17/47) of patients, respectively, having ≥50% BMPCs. S-phase analysis was available for 37 (79%) teclistamab and 40 (85%) talquetamab-treated patients, with median S-phase fractions of 2.6% (0–18.4%) and 4.6% (0.3–18.4%), respectively. An S-phase fraction ≥5% was observed in 22% (8/37) of teclistamab-treated patients compared with 38% (15/40) of talquetamab-treated patients. In the talquetamab cohort, 64% (30/47) received prior anti-BCMA directed therapy, and 36% (17/47) received talquetamab as bridging therapy before anti-BCMA CAR-T. 

Primary resistance (hematologic response <PR) occurred in 43% (20/47) of teclistamab-treated patients (4 stable disease (SD) and 16 progressive disease (PD)), compared with 21% (10/47) of talquetamab-treated patients (4 SD and 6 PD). Among teclistamab-treated patients, primary resistance was independently associated with higher BMPCs% (≥50% versus <50%: 68% vs. 25%, P = 0.006) and higher S-phase% (≥5% versus <5%: 88% vs. 34%, P = 0.011). These associations with teclistamab remained significant when restricted to patients without prior BCMA-directed therapy (BMPC ≥50% vs <50%: 71% vs. 16%, P = 0.001; S-phase ≥5% vs <5%: 83% vs. 33%, P = 0.029). In contrast, primary resistance to talquetamab was not associated with BMPC burden (BMPC ≥50% vs <50%: 18% vs. 23%, P = 0.727), S-phase% (≥5% vs <5%: 27% vs. 15%, P = 0.426), or use as bridging therapy before CAR-T (12% vs. 21%, P = 0.289).     

Conclusions 

BMPC ≥50% and S-phase ≥5% were associated with primary resistance to teclistamab, but not talquetamab, consistent with prior observations suggesting that elevated soluble BCMA in patients with high BMPC burden may create an antigen "sink" that reduces teclistamab efficacy. As BCMA- and GPRC5D-directed TCEs move earlier in therapy, baseline disease burden and proliferative index may help guide optimal antigen target selection. 

Will Bo Li: No relevant conflicts of interest to declare.